New treatment for blood diseases, such as leukemia and lymphoma.
HemoGenyx has raised $4.1M in total funding. The most recent round was Post-IPO Equity. The last funding was announced in April 2026.
HemoGenyx's investors include 43North, ScaleReady, Prevail Partners, Mint Capital.
HemoGenyx is headquartered in London, United Kingdom.
New treatment for blood diseases, such as leukemia and lymphoma.
HemoGenyx is at the Post-IPO Equity stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"HemoGenyx — Funding & Investors." VCBacked, April 28, 2026, https://www.vcbacked.co/company/hemogenyx. Accessed September 14, 2026.
VCBacked. (2026). HemoGenyx — Funding & Investors. Retrieved September 14, 2026, from https://www.vcbacked.co/company/hemogenyx
{{cite web |title=HemoGenyx — Funding & Investors |url=https://www.vcbacked.co/company/hemogenyx |website=VCBacked |access-date=September 14, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated